BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 37497430)

  • 1. Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody.
    Pan D; Richter J
    Cancer Manag Res; 2023; 15():741-751. PubMed ID: 37497430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
    Granger K; Gaffney KJ; Davis JA
    J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma.
    Martin TG; Mateos MV; Nooka A; Banerjee A; Kobos R; Pei L; Qi M; Verona R; Doyle M; Smit J; Sun W; Trancucci D; Uhlar C; van de Donk NWCJ; Rodriguez C
    Cancer; 2023 Jul; 129(13):2035-2046. PubMed ID: 36991547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nursing Considerations for Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma: Experience with Teclistamab from the MajesTEC-1 Study.
    Catamero D; Benito PB; Shenoy S; Doyle M; Fowler J; Kobos R; Banerjee A; Kruyswijk S
    Semin Oncol Nurs; 2024 Jun; 40(3):151621. PubMed ID: 38600011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
    Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos MV; Krishnan A
    Lancet; 2021 Aug; 398(10301):665-674. PubMed ID: 34388396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma.
    Pillarisetti K; Powers G; Luistro L; Babich A; Baldwin E; Li Y; Zhang X; Mendonça M; Majewski N; Nanjunda R; Chin D; Packman K; Elsayed Y; Attar R; Gaudet F
    Blood Adv; 2020 Sep; 4(18):4538-4549. PubMed ID: 32956453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teclistamab-cqyv: The First Bispecific T-Cell Engager Antibody for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma.
    Hua G; Scanlan R; Straining R; Carlson DS
    J Adv Pract Oncol; 2023 Mar; 14(2):163-171. PubMed ID: 37009408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience.
    Dima D; Davis JA; Ahmed N; Jia X; Sannareddy A; Shaikh H; Shune L; Kaur G; Khouri J; Afrough A; Strouse C; Lochner J; Mahmoudjafari Z; Raza S; Valent J; Anderson LD; Anwer F; Abdallah AO; Hashmi H
    Transplant Cell Ther; 2024 Mar; 30(3):308.e1-308.e13. PubMed ID: 38151105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas.
    Martens AWJ; Rietveld JM; de Boer R; Peters FS; Ngo A; van Mil LWHG; de Heer K; Spaargaren M; Verkleij CPM; van de Donk NWCJ; Adams HC; Eldering E; van Noesel CJM; Verona R; Kater AP
    Cancer Res Commun; 2022 May; 2(5):330-341. PubMed ID: 36875718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
    Landgren O; Nadeem O
    Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teclistamab: First Approval.
    Kang C
    Drugs; 2022 Nov; 82(16):1613-1619. PubMed ID: 36352205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Adverse Reactions for BCMA-Directed Therapy in Relapsed Multiple Myeloma: A Focused Review.
    Khanam R; Faiman B; Batool S; Najmuddin MM; Usman R; Kuriakose K; Ahmed A; Rehman MEU; Roksana Z; Syed Z; Anwer F; Raza S
    J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study.
    Nooka AK; Rodriguez C; Mateos MV; Manier S; Chastain K; Banerjee A; Kobos R; Qi K; Verona R; Doyle M; Martin TG; van de Donk NWCJ
    Cancer; 2024 Mar; 130(6):886-900. PubMed ID: 37960969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teclistamab: Mechanism of action, clinical, and translational science.
    Guo Y; Quijano Cardé NA; Kang L; Verona R; Banerjee A; Kobos R; Chastain K; Uhlar C; Pillarisetti K; Doyle M; Smit J; Haddish-Berhane N; Ouellet D
    Clin Transl Sci; 2024 Jan; 17(1):e13717. PubMed ID: 38266057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Panel Interview of ONcology practices with Emergent Experience of teclistamab in the Real world: the TecPIONEER Study.
    Derman BA; Roach M; Lin D; Wu B; Murphy R; Kim N; Doyle M; Prood N; Fowler J; Marshall A; Jamaleddine A; Paner-Straseviciute A
    Curr Med Res Opin; 2024 May; ():1-6. PubMed ID: 38745451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma.
    Verkleij CPM; Frerichs KA; Broekmans M; Absalah S; Maas-Bosman PWC; Kruyswijk S; Nijhof IS; Mutis T; Zweegman S; van de Donk NWCJ
    Oncotarget; 2020 Nov; 11(45):4076-4081. PubMed ID: 33227097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progressive Multifocal Leukoencephalopathy Unmasked by Teclistamab in a Refractory Multiple Myeloma Patient.
    Arvanitis P; Farmakiotis D; Pelcovits A
    Curr Oncol; 2024 May; 31(5):2670-2678. PubMed ID: 38785483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1.
    Cortes-Selva D; Perova T; Skerget S; Vishwamitra D; Stein S; Boominathan R; Lau OS; Nielsen K; Davis C; Patel JH; Banerjee A; Stephenson T; Uhlar C; Kobos R; Goldberg JD; Pei L; Trancucci D; Girgis S; Wang Lin SX; Wu LS; Moreau P; Usmani SZ; Bahlis NJ; van de Donk NWCJ; Verona R
    Blood; 2024 Apr; ():. PubMed ID: 38657201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
    Zhao J; Ren Q; Liu X; Guo X; Song Y
    J Hematol Oncol; 2023 Aug; 16(1):92. PubMed ID: 37537597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Talquetamab in multiple myeloma.
    Liu L; Krishnan A
    Haematologica; 2024 Mar; 109(3):718-724. PubMed ID: 37855056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.